Full-Time
Confirmed live in the last 24 hours
Develops cell therapy for chronic kidney disease
Mid
Winston-Salem, NC, USA
Position based in cGMP Manufacturing sites.
ProKidney focuses on treating Chronic Kidney Disease (CKD) through a novel cell therapy called rilparencel. This therapy aims to preserve kidney function in patients with advanced CKD, potentially delaying or eliminating the need for dialysis, which is often the only option for these patients. ProKidney is currently in the late stages of clinical trials, with early data indicating that rilparencel could effectively maintain kidney function. Unlike many competitors, ProKidney specifically targets the CKD market, which affects over 35 million adults in the U.S., and aims to fill a critical gap in treatment options. The company's goal is to provide a groundbreaking alternative to dialysis, significantly improving the quality of life for CKD patients.
Company Stage
IPO
Total Funding
$559.3M
Headquarters
Winston-Salem, North Carolina
Founded
N/A
Help us improve and share your feedback! Did you find this helpful?